AstraZeneca raised its sales and earnings forecasts for the year on Thursday, showing resilience after seeing off a $118 billion takeover approach from rival Pfizer two months ago. Photo: Bloomberg

AstraZeneca raised its sales and earnings forecasts for the year on Thursday, showing resilience after seeing off a $118 billion takeover approach fr(...)

Online grocery group Ocado is set to make its first annual profit since being set up by three former Goldman Sachs bankers in 2000.

It’s taken almost a decade and a half but, at last, online grocery group Ocado is set to make its first annual profit since being set up by three form(...)

AstraZeneca chief executive Pascal Soriot will address a cancer conference in Chicago. Photograph: Luke MacGregor/Reuters

AstraZeneca will this week attempt to show investors why it rejected Pfizer’s near-£70 billion takeover offer as its chief executive flies to the Uni(...)

PFIZER’S £69 billion bid for AstraZeneca may be dead in the water, for now at least, but the Anglo-Swedish pharmaceuticals giant has some hard work ah(...)

Ian Read, chairman and chief executive of Pfizer leaves Portcullis House after attending a parliamentary business and enterprise committee hearing on the possible takeover of AstraZeneca, in London.

As Westminster grillings go, the enquiry into Pfizer’s proposed £63 billion (€77 billion) takeover bid for AstraZeneca was a relatively restrained aff(...)

The furore created by Pfizer’s  £63 billion (€77 billion) bid for AstraZeneca  neared fever pitch yesterday. Photographer: Bloomberg

The furore created by the £63 billion (€77 billion) bid for Britain’s number-two pharmaceuticals group neared fever pitch yesterday, as politicians de(...)

Pascal Soriot, chief executive of  AstraZeneca:  said the future of its neuroscience and anti-infection businesses was under review and he hoped to announce news “in the near future”.

Pascal Soriot has set out a manifesto for AstraZeneca’s continued independence by announcing the possible sale or spin-off of non-core units in(...)

AstraZeneca will take pretax impairment charges of $275 million to non-core R&D expense in the first quarter of 2014 as part ofa wider restructuring programme. Photograph: Paul Thomas/Bloomberg

AstraZeneca has agreed to sell its Alderley Park research site in northern England to a public-private partnership group as it moves drug disco(...)

AstraZeneca expects to return to growth faster than analysts currently predict after a wave of drug patent expiries. Photo: Bloomberg

AstraZeneca expects to return to growth faster than analysts currently predict after a wave of drug patent expiries, with 2017 revenue likely to be br(...)

AstraZeneca is to buy out its joint venture with Bristol-Myers Squibb in a deal worth up to $4.3 billion, as it seeks to strengthen its limited range of innovative products and become a leading supplier of diabetes medicines

AstraZeneca is to buy out its joint venture with Bristol-Myers Squibb in a deal worth up to $4.3 billion, as it seeks to strengthen its limited range (...)